PMID- 37859468
OWN - NLM
STAT- MEDLINE
DCOM- 20231207
LR  - 20231221
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 32
IP  - 1
DP  - 2024 Jan 1
TI  - Arginase-1 is More Specific Than Hepatocyte Paraffin 1 for Differentiating 
      Hepatocellular Carcinomas With Cytoplasmic Clearing from Nonhepatocellular Clear 
      Cell Tumors in Liver Biopsies.
PG  - 37-43
LID - 10.1097/PAI.0000000000001169 [doi]
AB  - Arginase-1 (Arg1) and hepatocyte paraffin antigen 1 (HepPar1) are specific and 
      sensitive markers of hepatocellular differentiation. HepPar1 is a granular 
      cytoplasmic immunostain that may be negative in hepatocellular carcinoma (HCC) 
      with cytoplasmic clearing. Arg1 shows uniform cytoplasmic positivity and frequent 
      nuclear positivity. This study was undertaken to determine the staining pattern 
      of Arg1 in HCC with cytoplasmic clearing and compare its use to HepPar1. Fifteen 
      resected HCCs with cytoplasmic clearing and 31 biopsies of clear cell liver 
      tumors (14 HCCs and 17 nonhepatocellular tumors) were identified. Resections were 
      stained with Arg1 to characterize the pattern, intensity, and extent of Arg1 
      positivity. Biopsies were stained with Arg1 (n=31) and HepPar1 (n=28). In all, 
      13/15 resected and 11/14 biopsied HCCs with cytoplasmic clearing showed nuclear 
      positivity for Arg1. Both Arg1 and HepPar1 stained significantly more HCCs than 
      nonhepatocellular tumors (13/14 and 11/12, respectively, with P <0.0001 and P 
      =0.0018, respectively). However, HepPar1 stained significantly more 
      nonhepatocellular tumors (5/12) than Arg1 (0/17, P =0.0445). Arg1 frequently 
      displayed nuclear positivity, and interobserver agreement was better for Arg1 ( K 
      =0.93 vs. 0.79). Overall, Arg1 is more specific than HepPar1 for differentiating 
      HCC with cytoplasmic clearing from nonhepatocellular clear cell tumors in the 
      liver. Its staining characteristics, including nuclear positivity, make it easier 
      to interpret in combination with morphology, improving interobserver variability, 
      and it stains significantly fewer mimics than HepPar1.
CI  - Copyright (c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Larson, Brent K
AU  - Larson BK
AD  - Department of Pathology and Laboratory Medicine Cedars-Sinai Medical Center, Los 
      Angeles, CA.
FAU - Dhall, Deepti
AU  - Dhall D
AD  - Department of Pathology, University of Alabama at Birmingham, Birmingham, AL.
FAU - Guindi, Maha
AU  - Guindi M
AD  - Department of Pathology and Laboratory Medicine Cedars-Sinai Medical Center, Los 
      Angeles, CA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231020
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 8002-74-2 (Paraffin)
RN  - EC 3.5.3.1 (Arginase)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - Paraffin
MH  - *Liver Neoplasms/pathology
MH  - Arginase
MH  - Biomarkers, Tumor/analysis
MH  - Immunohistochemistry
MH  - Hepatocytes/pathology
MH  - Biopsy
MH  - Diagnosis, Differential
COIS- The authors declare no conflict of interest.
EDAT- 2023/10/20 06:42
MHDA- 2023/12/07 12:42
CRDT- 2023/10/20 03:43
PHST- 2021/11/07 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/12/07 12:42 [medline]
PHST- 2023/10/20 06:42 [pubmed]
PHST- 2023/10/20 03:43 [entrez]
AID - 00129039-990000000-00142 [pii]
AID - 10.1097/PAI.0000000000001169 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2024 Jan 1;32(1):37-43. doi: 
      10.1097/PAI.0000000000001169. Epub 2023 Oct 20.